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CLINICAL HETEROGENEITY OF PRIMARY
FAMILIAL BRAIN CALCIFICATION DUE TO A
NOVEL MUTATION IN PDGFB
Primary familial basal ganglia calcification (PFBC)
(previously known as idiopathic basal ganglia calci-
fication or Fahr disease) is an autosomal dominant
neurodegenerative disorder characterized by bilat-
eral cerebral calcification primarily affecting the
basal ganglia. Recently, mutations in SLC20A2,1
PDGFRB,2 and PDGFB3,4 have been identified as
causing PFBC. However, other than the original
study,3 there has been a paucity of descriptions of
families with PFBC.5
Herein, we describe 4 cases of PFBC within a fam-
ily due to a novel mutation in exon 4 of the PDGFB
gene (c.C3657T:p.P122L) highlighting significant
phenotypic heterogeneity.
Cases. Patient III.2. A 31-year-old woman presented
with acute psychosis. She was diagnosed in childhood
with mild learning difficulties, but reached normal
motor milestones. Over the next 6 years, she had
recurrent episodes of psychosis and depression requir-
ing admission. At age 36, a CT scan of her head
revealed basal ganglia calcification precipitating neu-
rologic referral (figure, A.b).
Examination revealed jerky ocular pursuit, gener-
alized chorea, and midline ataxia. Investigations re-
vealed a normal full blood count, biochemistry, and
autoantibodies. An EEG showed no encephalopathic
features.
There was no family history of any neurologic dis-
order; however, the examining neurologist noted that
the patient’s mother, accompanying her to clinic, was
ataxic (patient II.4).
Patient II.4.A retired shop worker was referred aged
60 years (figure). Both parents died in their 70s with
no neurologic symptoms before death. She had 3
siblings, none of whom she remained in contact with.
She had episodic psychosis and depression for
more than 20 years, and a 2-year history of falls and
unsteady gait. Medical history included hypertension
and heavy smoking. Examination revealed a severe
midline ataxia with jerky ocular pursuit. There were
no cognitive abnormalities or extrapyramidal features.
Serum biochemistry (including calcium and phos-
phate) was normal. A muscle biopsy showed normal
histology, normal mitochondrial biochemical studies,
and no mitochondrial DNA deletions. An EEG re-
vealed transient sharp waves in the temporal regions.
MRI showed calcium deposition in the globus pal-
lidus and dentate (figure, A.d).
Over the next 5 years, her ataxia progressed but
cognition remained normal (Mini-Mental State
Examination score 28/30 at age 66).
Patient III.5. A woman aged 40 years was referred
with a 2-year history of gait disturbance. She had
no psychiatric history, cognitive symptoms, or evi-
dence of abnormal movements. Examination revealed
normal cognition, but a midline ataxia. A CT brain
scan showed bilateral calcification of the globus pal-
lidus (figure, A.c). Three years later, she developed
a complex motor tic, and dystonic posturing of both
feet. Formal neuropsychometry remained normal.
Patient IV.4. A 20-year-old woman was referred
with a gait disturbance. She had no other medical
or psychiatric history. Neurologic examination was
normal. Brain MRI revealed small frontal noncalci-
fied white matter changes not in keeping with PFBC,
and no evidence of calcium in the basal ganglia even
with susceptibility-weighted imaging (figure, A.a).
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Patients III.1 and III.4.Aged 42 and 46 years, respec-
tively, patients III.1 and III.4 were clinically unaf-
fected. Patient III.1 died of a traumatic injury with
no evidence of basal ganglia calcification at autopsy.
Patient III.4 refused imaging studies.
Exome sequencing.Whole-exome sequencing was per-
formed on patients III.2, II.4, III.5, and IV.4 (appendix
e-1 on the Neurology® Web site at Neurology.org)
revealing a shared novel missense mutation in exon 4
of PDGFB (c.C3657T:p.P122L), not seen in the 1000
Genomes or ESP6500 database (figure, C), and pre-
dicted to be pathogenic by 4 software programs and
conserved across all species (MutationTaster). This
mutation was confirmed present in cases and absent
in unaffected relatives with Sanger sequencing
(III.1 and III.4). The p.P122L mutation is in the
same exon as published pathogenic alleles.3,6
Discussion. These cases highlight the phenotypic
heterogeneity of mutations in PDGFB. Two patients
exhibited an early psychiatric phenotype followed by
Figure Neuroimaging features and genotype details of affected individuals
(A) CT andMRI scans of cases. (A.a) Case IV.4 (age 20 years): T2MRI scan with no evidence of calcium deposition within the basal ganglia. (A.b) Case III.2 (age
36 years): CT scan showing calcium deposition in the caudate, lentiform nuclei, and thalamus. (A.c) Case III.5 (age 40 years): CT scan showing isolated subtle
calcium deposition in the globus pallidus. (A.d) Case II.4 (age 66 years): T1 MRI showing calcification in the globus pallidus together with periventricular and
pontine vascular white matter changes. (B) Pedigree of the family with the PDGFB p.P122L mutation. Black 5 affected individuals; clear 5 unaffected. (C)
Details of the mutation found in affected individuals. MAF 5 minor allele frequency.
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late-onset ataxia or chorea; an isolated movement
disorder was identified in a third. All 3 had ataxia,
which has been described in isolated cases,5 but not
consistently in PDGFB families.3 In addition, the
ataxia in our cases occurred without obvious
cerebellar calcification. This suggests that (1) the
mechanism may not be primarily mediated by
calcium deposition (although we cannot exclude the
presence of microcalcification), and (2) there is
significant clinical overlap with common neurologic
and psychiatric disorders.5 Our data also show a
heterogeneous radiologic phenotype that may be
much milder than previously described,3 and similar
to PDGFRB families.7 In keeping with this, case IV.4
showed no basal ganglia calcification and a normal
neurologic examination at age 20 years, providing
the first evidence of potential incomplete radiologic
penetrance for a pathogenic PDGFB mutation,
highlighting that normal imaging does not exclude
the diagnosis of PFBC.
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